The microscopic pathogen that is threatening global health and wreaking havoc from Singapore to Seoul, Tokyo to New York and Berlin to Milan is clearly reshaping the 2020 global outlook. But it should not derail the current momentum driving sustainability investing and corporate governance.
The future shape of the economic crisis driven by the federal government’s inadequate response to the coronavirus pandemic are coming into focus. The widespread social isolation that has sent both the demand for and production of goods and services into a free-fall reflects our spotty knowledge about the contagiousness and lethality of the virus. At the same time, we don’t know where hospital admissions will spike next. These new facts of life point to two potential economic scenarios, based on aspects of the virus that are beyond our control.
Medicine in the Age of Pandemics: why our innovation system for new drug discovery is failing and how to fix it
Covid-19 is our wake-up call. Deadly pandemics are expected to keep growing in the future and our innovation system for life-saving drug development is ill equipped to deal with it. Here is why and how to fix it.
The ongoing Covid-19 crisis can probably be seen as a “black swan” not only for China but also the whole world. It is largely unpredictable but with severe consequences.
There is no doubt that China has suffered the most from this crisis economically, socially and politically. However, it is highly debatable whether China or the Communist Party is approaching an inflection point of possible breakup or imminent revolution.
The outbreak of the 2019 novel coronavirus is so potentially impactful that we are devoting this entire edition to the epidemic, to an attempt to gauge its seriousness. Some stories are so big that it is hard to get your arms around them and this one definitely fits that category. Social media wasn't a factor during the 2003 SARS epidemic. The Chinese economy was a much smaller percentage of global GDP, and travel to and from China was far less common. So a simple comparison to SARS is not enough.
Co-authored with Jeff Jones, Chief Commercial and Strategy Officer for Conifer Health Solutions.
Co-authored with John Kerins, Director in Cain Brother’s Corporate M&A Advisory practice.